[
  {
    "ts": null,
    "headline": "2 High-Yield Dividend Stocks Too Cheap to Ignore",
    "summary": "They are both yielding above 5%.",
    "url": "https://finnhub.io/api/news?id=598561542817747752405868e67a038d2a82d95558c3739b3c77c9e57b0d6683",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760885820,
      "headline": "2 High-Yield Dividend Stocks Too Cheap to Ignore",
      "id": 137162452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "They are both yielding above 5%.",
      "url": "https://finnhub.io/api/news?id=598561542817747752405868e67a038d2a82d95558c3739b3c77c9e57b0d6683"
    }
  },
  {
    "ts": null,
    "headline": "XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer",
    "summary": "NEW YORK & NORTHBROOK, Ill., October 19, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, \"Astellas\") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a",
    "url": "https://finnhub.io/api/news?id=f4ca7f9aeac32df9ce5886fae228ca1af8abef9e81db1b708071fbed6fc3dc10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760861700,
      "headline": "XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer",
      "id": 137162453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK & NORTHBROOK, Ill., October 19, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, \"Astellas\") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a",
      "url": "https://finnhub.io/api/news?id=f4ca7f9aeac32df9ce5886fae228ca1af8abef9e81db1b708071fbed6fc3dc10"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer",
    "summary": "NEW YORK, October 19, 2025--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated pati",
    "url": "https://finnhub.io/api/news?id=c98dc7929c9a0c6b001928a3f64b6c81787ef7baf55bc94401c68ba0c110a683",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760855400,
      "headline": "Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer",
      "id": 137162455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, October 19, 2025--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated pati",
      "url": "https://finnhub.io/api/news?id=c98dc7929c9a0c6b001928a3f64b6c81787ef7baf55bc94401c68ba0c110a683"
    }
  }
]